Combination Therapy with Linagliptina and Glibenclamida

Introduction to Combination Therapy

The American College of Cardiology recommends that linagliptina and glibenclamida can be used together, but with caution due to the increased risk of hypoglycemia, and considers reducing the dose of glibenclamida when initiating combination therapy 1, 2

Linagliptina is a DPP-4 inhibitor that increases endogenous GLP-1 levels, improving insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner, as recommended by the American Diabetes Association 3
Glibenclamida is a second-generation sulfonylurea that stimulates insulin release from pancreatic beta cells, regardless of glucose levels, according to the American College of Cardiology 1

The combination of DPP-4 inhibitors with sulfonylureas significantly increases the risk of hypoglycemia (approximately 50% more) compared to sulfonylurea alone, as reported by the Kidney International 3
The American College of Cardiology recommends reducing the initial dose of sulfonylurea (glibenclamida) by approximately 50% when starting treatment with linagliptina to prevent hypoglycemic events 5

Linagliptina does not require dose adjustment in patients with any degree of renal insufficiency, which differentiates it from other DPP-4 inhibitors, according to the Kidney International 2
Glibenclamida is generally not recommended in patients with chronic kidney disease due to the increased risk of prolonged hypoglycemia, as stated by the American Diabetes Association 1, 2

When initiating combination therapy, consider reducing the dose of glibenclamida to 50% of the usual dose or to no more than 50% of the maximum recommended dose, as recommended by the Journal of the American College of Cardiology 5
Maintain the standard dose of linagliptina at 5 mg once daily, according to the Kidney International 2
Closely monitor blood glucose levels during the first weeks of combination therapy, as advised by the American College of Cardiology 5

Inform patients about the symptoms of hypoglycemia and how to manage it, as recommended by the American College of Cardiology 5
Emphasize the importance of maintaining regular meal schedules, according to the American Diabetes Association 3

In elderly patients or those with renal insufficiency, the risk of hypoglycemia with this combination is even higher, as reported by the Kidney International 2
If the patient experiences recurrent episodes of hypoglycemia, consider further reducing the dose of glibenclamida or switching to another hypoglycemic agent with a lower risk, as recommended by the American College of Cardiology 5, 3

In patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 receptor agonists may be preferred over the combination of linagliptina and glibenclamida, according to the American Diabetes Association 4, 3